FDA issued a Class I enforcement action. Affects Boston Scientific Corporation. Reason: Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting fro.
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange...
Worldwide distribution. US Nationwide including Puerto Rico; Algeria, Argentina, Austria, Belgium, Brazil, Canada, CHILE, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Finland, France, Ge...